COMBIPATCH 0.05/0.25mg Rx

Select the drug indication to add to your list

COMBIPATCH 0.05/0.25mg

Menopause and HRT
Only 4 drugs may be compared at once

Generic Name and Formulations:

Estradiol 0.05mg + norethindrone acetate 0.25mg; per day; transdermal system.

Select therapeutic use:

Indications for COMBIPATCH 0.05/0.25mg:

In women with an intact uterus: moderate-to-severe vasomotor symptoms of menopause, vulvar and vaginal atrophy, hypoestrogenism.

Adult:

Use lowest effective dose for shortest duration. Apply to smooth, clean, dry area of lower abdomen (avoid breasts, waistline). Continuous combined regimen: 1 CombiPatch twice weekly for 28-day cycle; repeat. Continuous sequential regimen (use with 0.05mg/day estrogen patch): Use estrogen-only patch for first 14 days of cycle, then 1 CombiPatch twice-weekly for second 14 days of 28-day cycle; repeat. Rotate application site. Reevaluate at 3–6 month intervals to assess need.

Children:

Not applicable.

Contraindications:

Undiagnosed abnormal genital bleeding. Known, suspected or history of breast cancer. Known or suspected estrogen-dependent neoplasia. Active DVT, PE or history of. Active arterial thromboembolic disease or history of. Known hepatic impairment. Known protein C, protein S, or antithrombin deficiency or other known thrombophilic disorders. Pregnancy (Cat.X).

Warnings/Precautions:

Not for prevention of cardiovascular disease or dementia. Increased risk of cardiovascular disorders (eg, stroke, DVT, VTE); discontinue if occurs or suspected. Discontinue at least 4–6 weeks before surgery type associated with increased risk of thromboembolism or during prolonged immobilization. Endometrial, breast, or ovarian cancer. Risk of probable dementia in women ≥65yrs of age. Gallbladder disease. Bone disease associated with hypercalcemia. Visual abnormalities. History of hypertriglyceridemia. Discontinue if cholestatic jaundice, pancreatitis, hypercalcemia, or retinal vascular lesions occur. Monitor thyroid function. Conditions aggravated by fluid retention. Hypoparathyroidism. Endometriosis. Hereditary angioedema. Asthma. Diabetes. Epilepsy. Migraine. Porphyria. SLE. Hepatic hemangiomas. Do initial complete physical and repeat yearly (include Pap smear, mammogram, BP). Reevaluate periodically. Nursing mothers.

Interactions:

CYP3A4 inducers/inhibitors: may affect estrogen drug metabolism. May interfere with lab tests (eg, thyroid, PT, coagulation factors, glucose tolerance, HDL/LDL, triglycerides, hormone concentrations, other binding or plasma proteins).

See Also:

COMBIPATCH 0.05/0.14mg

Pharmacological Class:

Estrogen + progestin.

Adverse Reactions:

See full labeling. Headache, breast pain, dysmenorrhea, menstrual disorder, back pain, asthenia, respiratory disorders, application site reactions; elevated BP, hypercalcemia, thromboembolic disorders, gallbladder disease, endometrial cancer or hyperplasia.

How Supplied:

Patches—8